[Postoperative adjuvant immunochemotherapy with bestatin for stomach cancer. Randomized controlled trial: first report].
The effectiveness of Bestatin combined with Mitomycin-C, FT-207 for treating gastric cancer was investigated in a prospective randomized controlled study. All patients had undergone gastrectomy during the period from November 1980 to July 1983. Three-year survival rates revealed no difference between groups given or not given Bestatin. The effectiveness of Bestatin was confirmed by postoperative changes revealed by liver function test, especially GOT and GPT. No side effect due to Bestatin was detected.
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007930:Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011182:Postoperative Care; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D007930:Leucine; C012211:ubenimex